Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2019-08-08 Capital/Financing Update
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2019, by Titan Pharmaceuticals, Inc. It reports the entry into a material definitive agreement related to a securities purchase agreement involving issuance of common stock and warrants. The document includes details about the transaction, terms of the securities, and related agreements. It also references exhibits such as the purchase agreement and placement agency agreement. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising transaction and related agreements, which fits the definition of a Capital/Financing Update. The document length (8639 characters) is sufficient to be the report itself, not just an announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-08-08 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering, specifically a share and warrant offering. It includes detailed terms of the offering, pricing, placement agent fees, risk factors, and legal disclaimers. It references a shelf registration statement and is clearly an offering document rather than a financial report or earnings release. The document is not an annual or quarterly report, audit report, call transcript, or any other financial or governance report. It is a capital raising document describing the issuance of new shares and warrants to investors. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or regulatory filing. Confidence is high due to the explicit nature of the document and its SEC filing type (424B5).
2019-08-08 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) and relates to the offer and sale of common stock up to $4,000,000. It references a sales agreement and details about the public float and sales limitations under Form S-3. The document is a registration and offering update, typical of capital raising activities. It is not a full financial report, earnings release, or management discussion. The document length is short (2390 characters) and it is clearly a filing related to capital raising and financing activities. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP).
2019-08-08 English
SABBY 13G TTNP 8.07.19
Major Shareholding Notification
2019-08-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes an event where the European Commission approved a drug, and the company is issuing shares related to a convertible loan agreement. There is no detailed financial data or comprehensive report content, but rather an announcement of a significant corporate event. The document length is 4025 characters, which is relatively short and consistent with an 8-K filing. This type of filing is best classified under Regulatory Filings (RNS) as it does not fit into other specific categories like Annual Report, Earnings Release, or Capital/Financing Update, but is a regulatory announcement of a material event.
2019-06-27 English
OWNERSHIP DOCUMENT
Director's Dealing
2019-06-07 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.